Novartis Aktie

Novartis ab 0 Euro bei Finanzen invest ordern (zzgl. Spreads)

WKN: 904278 / ISIN: CH0012005267

<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs
>
<
Aktion
Portfolio
Watchlist
>
27.10.2026 06:59:54

Press Release: Novartis delivered sales growth -3-

at an upcoming medical congress.

Kisqali The six-year follow-up analysis of the Phase III NATALEE

(ribociclib) trial showed a clinically meaningful overall survival

(OS) benefit with Kisqali plus endocrine therapy (ET)

versus ET alone in the broadest HR+/HER2- early breast

cancer (eBC) population at high risk of recurrence,

reducing the risk of death by nearly 20%. Patients

had been off Kisqali treatment for a median of 38

months, with clinical benefit continuing to deepen

after treatment completion. The safety profile remained

consistent with previous analyses. Data were presented

at ESMO 2026.

LOU064 Novartis has discontinued the Phase III study of remibrutinib

(remibrutinib) in generalized myasthenia gravis (gMG) following a

futility analysis, which indicated the treatment was

unlikely to meet its efficacy objectives. No safety

concerns were identified, and there is no impact on

remibrutinib studies in other indications.

Selected Novartis completed the acquisition of Myricx Bio,

transactions strengthening the oncology pipeline with a new class

of antibody-drug conjugates (ADCs), including two

lead assets targeting B7-H3 and HER2, as well as a

broader payload platform with potential impact across

multiple solid tumor settings.

Novartis exercised its exclusive option to acquire

full global rights to Sironax's proprietary Brain

Delivery Module (BDM) platform, a next-generation

blood-brain barrier crossing technology with the potential

to transform the treatment of central nervous system

diseases.

Novartis entered into an exclusive global licensing

agreement with BoomRay Pharmaceuticals for an undisclosed

preclinical radioligand therapy asset, further strengthening

its radioligand therapy portfolio.

In October, Novartis entered into a strategic licensing

and option agreement with Abogen Biosciences to advance

RNA-encoded therapeutics, including an exclusive worldwide

license to ABO2203, a novel mRNA-encoded CD19xCD3

T-cell engager with the potential to transform the

treatment landscape for autoimmune diseases. The transaction

is subject to the completion of customary closing

conditions.

Capital structure and net debt

Retaining a good balance between investment in the business, a strong capital structure, and attractive shareholder returns remains a priority.

During the first nine months of 2026, Novartis repurchased 30.9 million shares for USD 4.7 billion on the SIX Swiss Exchange second trading line. These repurchases included 18.8 million shares (USD 2.8 billion) under the up-to USD 10 billion share buyback announced in July 2025 (with up to USD 4.9 billion still to be executed). In addition, 12.1 million shares (USD 1.8 billion) were repurchased to mitigate the anticipated full-year dilution related to participation plans of employees. Further, 2.0 million shares (USD 0.3 billion) were repurchased from employees. During the same period, USD 0.9 billion of equity-based compensation plan expenses were recognized to equity and 13.3 million shares were delivered to employees related to equity-based compensation plans from prior years. As a result, the total number of shares outstanding decreased by 19.6 million compared with December 31, 2025. These treasury share transactions resulted in an equity decrease of USD 4.1 billion and a cash outflow of USD 4.8 billion.

Net debt increased to USD 37.4 billion at September 30, 2026, compared with USD 21.9 billion at December 31, 2025. The increase was mainly due to the free cash flow of USD 14.0 billion being more than offset by the net cash outflow for M&A, intangible assets transactions and other acquisitions of USD 16.7 billion, the USD 9.1 billion annual dividend payment and cash outflows for treasury share transactions of USD 4.8 billion.

As of Q3 2026, the long-term credit rating for the company is Aa3 with Moody's Ratings and AA- with S&P Global Ratings.

2026 outlook

Barring unforeseen events; growth vs. prior year in

cc

Net sales Expected to grow low single-digit

Core operating income Expected to be in line to grow low single-digit

(from decline low single-digit)

Foreign exchange impact

If late-October exchange rates prevail for the remainder of 2026, the foreign exchange impact for the year would be positive 1 percentage point on net sales and positive 1 percentage point on core operating income. The estimated impact of exchange rates on our results is provided monthly on our website.

2027 Annual General Meeting

Nomination for election to the Board of Directors

The Novartis Board of Directors announced today that it is nominating Rajesh Jha for election to the Board. During a 36-year career at Microsoft, Mr. Jha held a series of senior leadership roles across software engineering, productivity platforms and enterprise technologies, and served on the company's Senior Leadership Team from 2016 until his retirement. Most recently, he served as Executive Vice President, Experiences + Devices, where he led the product teams for Microsoft 365, Office, Teams, Windows + Devices, and Dynamics, and played a key role in the integration of artificial intelligence across Microsoft's product portfolio. His extensive experience in technology, AI and large-scale digital platforms would add significantly to the Novartis Board of Directors.

Key figures(1)

Q3 Q3

2026 2025 % change 9M 2026 9M 2025 % change

USD USD USD USD

m(2) m(2) USD cc m(2) m(2) USD cc

------ ------ ---- ---- ------- ------- ---- ----

Net sales 14 522 13 909 4 4 42 043 41 196 2 0

------ ------ ---- ---- ------- ------- ---- ----

Operating income 1 843 4 501 -59 -61 10 828 14 028 -23 -24

------ ------ ---- ---- ------- ------- ---- ----

As a % of sales 12.7 32.4 25.8 34.1

---------------------- ------ ------ ------- -------

Net income 1 196 3 930 -70 -71 7 609 11 563 -34 -35

------ ------ ---- ---- ------- ------- ---- ----

EPS (USD) 0.63 2.04 -69 -70 4.01 5.94 -32 -33

------ ------ ---- ---- ------- ------- ---- ----

Net cash flows from

operating activities 5 503 6 571 -16 15 061 16 880 -11

------ ------ ---- ------- ------- ----

Non-IFRS measures

Free cash flow 5 111 6 217 -18 14 002 15 941 -12

------ ------ ---- ------- ------- ----

Core operating income 6 036 5 460 11 10 16 873 16 960 -1 -2

------ ------ ---- ---- ------- ------- ---- ----

As a % of sales 41.6 39.3 40.1 41.2

---------------------- ------ ------ ------- -------

Core net income 4 655 4 330 8 6 13 027 13 522 -4 -5

------ ------ ---- ---- ------- ------- ---- ----

Core EPS (USD) 2.46 2.25 9 8 6.85 6.94 -1 -3

------ ------ ---- ---- ------- ------- ---- ----

1. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 45 of the Condensed Interim Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year. 2. USD millions unless indicated otherwise.

Detailed financial results accompanying this press release are included in the Condensed Interim Financial Report at the link below:

https://www.novartis.com/sites/novartis_com/files/q3-2026-interim-financial-report-en.pdf

Disclaimer

This communication contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, that can generally be identified by words such as "expected," "anticipated," "can," "will," "continue," "ongoing," "growth," "launch," "expanding," "deliver," "accelerate," "guidance," "outlook," "priority," "potential," "momentum," "on track," "pipeline," "evidence," "progress," "emerging," or similar expressions, or by express or implied discussions regarding: potential new products, potential new indications for existing products, potential product launches or potential future revenues from any such products; or results of ongoing clinical trials; potential future, pending or announced transactions; potential future sales or earnings; strategy, plans, expectations or intentions, including discussions regarding our continued investment into new R&D capabilities and manufacturing; our capital structure. You should not place undue reliance on these statements. Such forward-looking statements are based on the current beliefs and expectations of management regarding future events and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in

(MORE TO FOLLOW) Dow Jones Newswires

October 27, 2026 02:00 ET (06:00 GMT)

Analysen zu Novartis AG

mehr Analysen
20.11.26 Novartis Neutral UBS AG
19.11.26 Novartis Sector Perform RBC Capital Markets
19.11.26 Novartis Hold Jefferies & Company Inc.
11.11.26 Novartis Hold Jefferies & Company Inc.
11.11.26 Novartis Hold Joh. Berenberg, Gossler & Co. KG (Berenberg Bank)
Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Novartis AG 136,80 -0,75% Novartis AG
Novartis AG (Spons. ADRS) 137,00 0,00% Novartis AG (Spons. ADRS)